Azurity gets FDA nod for oral liquid epilepsy drug

July 19, 2022

The U.S. FDA has approved Azurity Pharmaceuticals’ Zonisade, an oral liquid formulation drug for patients with epilepsy, the company announced this week. 

The approval makes the drug the first and only FDA-approved oral liquid formulation for zonisamide. The drug is now approved as adjunctive therapy for the treatment of partial seizures in adults and pediatric patients aged 16 years and older with epilepsy. 

Around the world, roughly 65 million people live with epilepsy. Characterized by repeated seizures, the neurological disorder often comes with comorbidities that could cause patients to develop difficulty swallowing or remembering to take tablets. 

Massachusetts-based Azurity purchased zonisamide, along with two other neurology treatments, from Eton Pharmaceuticals back in Feb. 2021

“We are excited about this approval as we continue to grow our portfolio of liquid medications that meet the individual needs of certain patients," said Azurity CEO Richard Blackburn.